Darbepoetin alfa + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

MDS

Conditions

MDS

Trial Timeline

Dec 21, 2011 → Sep 14, 2017

NCT ID

NCT01362140

About Darbepoetin alfa + Placebo

Darbepoetin alfa + Placebo is a phase 3 stage product being developed by Amgen for MDS. The current trial status is completed. This product is registered under clinical trial identifier NCT01362140. Target conditions include MDS.

What happened to similar drugs?

0 of 4 similar drugs in MDS were approved

Approved (0) Terminated (1) Active (3)

❌Roxadustat + PlaceboAstellas PharmaPhase 3

🔄Venetoclax + Azacitidine + PlaceboAbbViePhase 3

🔄Darbepoetin AlfaAmgenPhase 3

🔄APR-246 + azacitidine + AzacitidineAprea TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01362140	Phase 3	Completed	Dec 21, 2011	Sep 14, 2017	MDS
NCT00858364	Phase 3	Terminated	Jul 17, 2009	Jun 7, 2017	Non-Small Cell Lung Cancer
NCT00436748	Phase 3	Terminated	Sep 16, 2008	Mar 3, 2014	Anemia
NCT00364845	Phase 3	Terminated	Sep 1, 2006	Feb 1, 2009	Anemia
NCT00358215	Phase 3	Completed	Jun 1, 2006	Oct 11, 2012	Heart Failure
NCT00091858	Phase 3	Completed	Apr 1, 2004	Dec 1, 2006	Anemia
NCT00110955	Phase 3	Completed	Feb 1, 2004	Apr 1, 2005	Anemia
NCT03776032	Phase 3	Completed	Sep 14, 1999	Feb 27, 2002	Anemia

Competing Products

20 competing products in MDS

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
Roxadustat + Placebo	Astellas Pharma	Phase 3	32
KRN321	Kyowa Kirin	Phase 2	35
Azacitidine + Venetoclax	AbbVie	Phase 1	33
venetoclax + azacitidine	AbbVie	Phase 1	29
Venetoclax + Azacitidine + Placebo	AbbVie	Phase 3	44
venetoclax + azacitidine +/- donor lymphocyte infusion	AbbVie	Phase 1/2	36
Birabresib Dose 20 mg	Merck	Phase 1	21
Azacitidine and LDE255	Novartis	Phase 1	29
MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine)	Novartis	Phase 2	27
Panobinostat	Novartis	Phase 2	27
Azacitidine + Azacitidine plus Deferasirox	Novartis	Phase 2	27
Deferasirox, Vitamin D and Azacitidine	Novartis	Phase 1/2	28
LGH447 + LGH447 + midostaurin	Novartis	Phase 1	29
Panobinostat	Novartis	Phase 1	29
sabatolimab + azacitidine + venetoclax	Novartis	Phase 2	27
LBH589 + Epoetin Alfa	Novartis	Phase 2	27
Placebo + Romiplostim	Amgen	Phase 2	35
Darbepoetin Alfa	Amgen	Phase 3	40